ArticleFrontiers in nutrition2026
Vitamin B1 and sepsis: a prospective single-center study.
Article in Frontiers in nutrition, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: Vitamin B1 (VB1), an essential coenzyme in cellular energy metabolism, is postulated to modulate clinical outcomes in sepsis. However, the relationship between VB1 and sepsis remains inadequately explored both domestically and internationally, and its potential clinical value remains unclear. Therefore, this study aims to investigate the association between VB1 deficiency and the severity of sepsis, and to evaluate the potential clinical utility of VB1 in ameliorating sepsis-induced organ injury and coagulation dysfunction. Methods: A total of 67 patients from Inner Mongolia Baogang Hospital were enrolled in this study. Among them, 41 were assigned to the sepsis group (clinically diagnosed with sepsis), and the remaining 26 comprised the control group (patients with ordinary pneumonia who did not meet the clinical diagnostic criteria for sepsis). Serum VB1 levels were measured using ultra-high-performance liquid chromatography-tandem mass spectrometry from peripheral blood samples. Clinical and laboratory data were obtained from electronic medical records. Multivariate logistic regression analysis was employed to assess the potential of VB1 as an independent biomarker for sepsis. All statistical analyses were performed using SPSS version 27.0. Results: The sepsis group exhibited significantly lower VB1 levels than the control group ( Conclusion: VB1 levels exhibit an inverse association with key inflammatory biomarkers in patients with sepsis, and reduced VB1 concentration is independently associated with a higher prevalence of sepsis.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.